Differing approaches to experimental therapeutics: Are we a world apart?

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1649-1650

  Cripe, Timothy P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; E1A PROTEIN; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE;

ADENOVIRUS; ADENOVIRUS 3; ADENOVIRUS 5; ANTINEOPLASTIC ACTIVITY; CLINICAL EVALUATION; CLINICAL RESEARCH; CYTOLYSIS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; E1A GENE; EDITORIAL; EXPERIMENTAL THERAPY; FINLAND; GENE EXPRESSION; GOVERNMENT REGULATION; HEALTH PROGRAM; HTERT GENE; INFORMED CONSENT; JOB EXPERIENCE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ETHICS; MOLECULAR THERAPY; ONCOLYTIC VIROTHERAPY; RISK BENEFIT ANALYSIS; RISK REDUCTION; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; UNITED STATES; VIRUS GENE; VIRUS REPLICATION;

EID: 84866973006     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.174     Document Type: Editorial

References (2)

1. Hemminki, O, Diaconu, I, Cerullo, V, Pesonen, SK, Kanerva, A, Joensuu, T et al. (2012). Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther 20: 1821-1830.
2. Horstmann, E, McCabe, MS, Grochow, L, Yamamoto, S, Rubinstein, L, Budd, T et al. (2005). Risks and benefts of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895-904. (Pubitemid 40300298)